Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bismuth Quadruple Therapy Duration in Clarithromycin-Resistant H. pylori
KCT0004414Phase 4Completed
- Sponsor
- Il-Yang Pharmaceutical
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of proton pump inhibitor + bismuth subsalicylate + metronidazole + tetracycline in Helicobacter pylori infection (2 arms), sponsored by Il-Yang Pharmaceutical. Primary endpoint: Helicobacter pylori eradication rate. Started Mar 2020; status: completed.
02
Drugs
proton pump inhibitor + bismuth subsalicylate + metronidazole + tetracycline
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on KCT0004414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004414.